Biomarker Strategy Proposed to Forecast BCG Nonresponse in Bladder Cancer
A newly published review examines whether biomarkers can pinpoint high-risk bladder cancer patients who may not benefit from BCG. The authors propose a testing strategy, but specialists note that validation in clinical studies is still required.
The review focuses on high-risk bladder cancer and asks whether biological markers can reveal which patients are unlikely to respond to BCG. It considers a proposed testing approach built around that possibility. According to the summary, specialists caution that the idea still needs confirmation through clinical research before it can be considered reliable. This places the work at an early stage, where a concept is being examined rather than adopted.
If validated, such a biomarker strategy could affect high-risk bladder cancer patients by helping clinicians identify those less likely to benefit from BCG, potentially sparing them an ineffective treatment. It may also shape future research priorities and patient conversations. For now, the impact remains uncertain because clinical validation is pending. Patients and families may see hope in the proposal, but it is not yet an established tool.